罗格列酮影响2型糖尿病患者颈动脉内膜中层厚度及斑块的超声评价  

Ultrasonic Estimation of Effects of Rosiglitazone on Carotid Intima-Media Thickness and Plaque in Patients with Type 2 Diabetes Mellitus

作　　者：张鸿飞[1] 肖立中[2] 林晓云[1] 江志平[2] 

机构地区：[1]广东韶关大学医院,512005 [2]广东省粤北人民医院,512026

出　　处：《中国误诊学杂志》2005年第17期3208-3210,共3页Chinese Journal of Misdiagnostics

摘　　要：目的:应用颈动脉超声评价2型糖尿病患者罗格列酮长期治疗后颈动脉内膜中层厚度及斑块变化。方法:选择59例2型糖尿病并肥胖患者,随机分成对照组(n=29)与治疗组(n=30),后者加用罗格列酮治疗24个月,治疗前后应用高频超声检测颈动脉内膜中层厚度(IM T)及斑块,同时测定血清一氧化氮(NO)、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)。结果:与对照组比较,治疗组IM T及斑块检出率降低(P<0.01及0.05),血清NO增加,CRP、TNF-α降低(P<0.01);与治疗前比较,对照组IM T增加(P<0.01),斑块检出率及血清NO,CRP、TNF-α无明显变化(P>0.05)。结论:罗格列酮长期治疗能延缓2型糖尿病患者颈动脉粥样硬化进展,稳定斑块。Objective:To investigate the therapeutic effects of rosiglitazone on carotid intima-media thickness(IMT) and arterial plaque in patients with type 2 diabetes mellitus(DM) by carotid ultrasonography.Methods:59 cases of obese DM were randomly divided into two groups:Control group(n=29) received routine therapy alone,Treat group((n=)30) received therapy with rosiglitazone on the basis of routine therapy for 24 months.Carotid IMT and arterial plaque were measured by carotid ultrasonography before and after the treatment,serum nitric oxide(NO),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α) level were assayed also.Results:Compared with control group,the IMT and carotid arterial plaque were decreased after rosiglitazone treatment(P<0.01 and 0.05),serum NO increased,CRP,TNF-α decreased also(P<0.01).Compared with pretherapy,IMT in control group was increased(P<0.01),No significant change was found in percentage of detection of carotid arterial plaque and serum level of NO,CRP,TNF-α(P>(0.05)).Conclusion:Rosiglitazone can retard atherosclerosis progression and stable arterial plaque in obese patients with type 2 DM.

关 键 词：糖尿病 Ⅱ型/药物疗法 颈动脉疾病/超声检查 颈动脉/超声检查 血管内膜/超声检查 噻唑烷二酮类/治疗应用 

分 类 号：R587.2[医药卫生—内分泌]